Inhibrx Biosciences Enters Loan Agreement with Oxford Finance
Inhibrx Biosciences, a biopharmaceutical company with two programs in ongoing clinical trials, entered into a loan and security agreement with Oxford Finance, pursuant to which the lenders provided a five-year term loan facility for up to $150 million. “This enables...
Read moreDetails










